Research – Schizophrenia

The long term goal of this research is to minimize morbidity associated with psychotic disorders by developing injectable long-acting formulations of atypical antipsychotic agents for the treatment of schizophrenia and mania.

We have received an SBIR Phase 1 grant for this work from the National Institute of Mental Health. Our collaborators include Dr. Ross Baldessarini of the Maclean Hospital and Harvard Medical School.

Dr. Baldessarini is an internationally known neuroscientist and research psychopharmacologist who has made many contributions related to the basic scientific understanding of central monoaminergic systems, their involvement in the pathophysiology of neuropsychiatric disorders, and the interactions of antipsychotic and mood-altering agents with them.

Dr. Baldessarini was a Career Investigator of the NIMH 1970-2000, and is the author of over 1,400 publications, including the chapters on psychopharmacology in Goodman & Gilman's standard American textbook of pharmacology, The Pharmacological Basis of Therapeutics (McGraw Hill), as well as his own text, Chemotherapy in Psychiatry: Principles and Practice (Harvard University Press). He also serves on editorial boards of several leading neuroscience and psychiatric research journals. Among his many recognitions was election to the Scholars of Johns Hopkins University.